The Implementation of Pre-exposure Prophylaxis of Injectable Cabotegravir

Summary

Although CAB LA PrEP has been proven efficacious in blinded randomized controlled clinical trials, additional research is needed to evaluate effectiveness in real world settings as well as to identify effective implementation strategies. The proposed implementation study will assess the safety and effectiveness of open label CAB LA PrEP when offered at public health facilities to cisgender men and transgender or gender non-binary individuals who have sex with persons assigned male at birth. The study will also evaluate two nested implementation strategies, an mHealth education and decision support tool and a WhatsApp injection appointment reminder. The study will also assess overall facilitators and barriers to integrating CAB LA into existing oral PrEP services.

Timeline

Start

2022-09-20

Primary completion

2025-10

Completion

2026-02

Publications

• Torres TS, Hoagland B, Coutinho C, Silva MST, Moreira RI, Leite IC, Cunha M, Jalil EM, Cardoso SW, Trefiglio R, Farias A, Mourao MPG, Madruga JV, de Lima JN, Zonta R, O'Malley G, Moreira J, Simpson K, Pines HA, Rinehart AR, Pilgrim N, Luz PM, Benedetti M, Pimenta MC, Veloso VG, Grinsztejn B; ImPrEP CAB Brasil Study Group. Person-centered choice and mHealth support for same-day delivery of long-acting injectable cabotegravir (ImPrEP CAB Brasil): a prospective, open-label, multicenter, quasi-experimental implementation study. Lancet Reg Health Am. 2026 Jun 12;59:101522. doi: 10.1016/j.lana.2026.101522. eCollection 2026 Jul.
• Pimenta C, Mann CG, Hoagland B, Carvalheira E, Jalil C, Benedetti M, Fernandes N, Coutinho C, Jalil EM, Secco Torres Silva M, Trefiglio R, Farias A, Mourao MPG, Madruga JV, de Lima JN, Zonta R, O'Malley G, Veloso VG, Grinsztejn B, Torres TS; ImPrEP CAB-Brasil Study. Exploring perceptions and preferences for PrEP choice and of an mHealth intervention: insights from the ImPrEP CAB-Brasil study. J Int AIDS Soc. 2025 Jul;28 Suppl 2(Suppl 2):e26493. doi: 10.1002/jia2.26493.
• Pimenta MC, Torres TS, Hoagland B, Cohen M, Mann CG, Jalil CM, Carvalheira E, Freitas L, Fernandes N, Castanheira D, Benedetti M, Moreira J, Simpson K, Trefiglio R, O'Malley G, Veloso VG, Grinsztejn B. Preparing for the Implementation of Long-Acting Injectable Cabotegravir for HIV Pre-Exposure Prophylaxis Within the Brazilian Public Health System (ImPrEP CAB Brasil): Qualitative Study. JMIR Public Health Surveill. 2024 Oct 24;10:e60961. doi: 10.2196/60961.
• Grinsztejn B, Torres TS, Hoagland B, Jalil EM, Moreira RI, O'Malley G, Shade SB, Benedetti MR, Moreira J, Simpson K, Pimenta MC, Veloso VG; ImPrEP CAB-Brasil Study Team. Long-Acting Injectable Cabotegravir for HIV Preexposure Prophylaxis Among Sexual and Gender Minorities: Protocol for an Implementation Study. JMIR Public Health Surveill. 2023 Apr 19;9:e44961. doi: 10.2196/44961.

Drugs

Indications